Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: A pilot study

A. Fagotti, I. Paris, F. Grimolizzi, F. Fanfani, G. Vizzielli, A. Naldini, G. Scambia

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objectives: To assess feasibility, complications and efficacy of secondary surgical cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in a selected group of platinum-sensitive recurrent ovarian cancer patients. Methods: Recurrent ovarian cancer patients with a platinum-free interval of at least 6 months were prospectively enrolled. After complete CRS they were submitted to intraperitoneal perfusion of oxaplatinum (460 mg/m 2) heated to 41.5 °C for 30 min. Then they received systemic chemotherapy with taxotere 75 mg/m 2 and oxaliplatin 100 mg/m 2 for 6 cycles. Patients were followed up routinely until recurrence or death. Results: Twenty-five recurrent ovarian cancer patients were valuable for the study. The median Platinum Free Interval (PFI) was 25 months (range 7-67). The majority of the patients (76%) had diffuse carcinosis. Nobody had ascites. An optimal residual disease was obtained in all patients. The median duration of CRS + HIPEC was 312 min (range138-619). Median intensive care unit (ICU) stay was 2 days (1-6), median hospital stay was 13 days (7-30). Post-operative major complications were observed in 7 patients (28%). Post-operative mortality was 0%. With a median follow-up time of 18 months (range 3-38), 24 patients (96%) are alive, but seven women (28%) have relapsed. Conclusions: Adequate pre-operative selection can improve feasibility of CRS and HIPEC. Morbidity rate is comparable to aggressive cytoreduction without HIPEC. Although associated with some post-operative morbidity, long-term results are encouraging, waiting for larger series and longer follow-up data.

Original languageEnglish
Pages (from-to)335-340
Number of pages6
JournalGynecologic Oncology
Volume113
Issue number3
DOIs
Publication statusPublished - Jun 2009

Fingerprint

oxaliplatin
Platinum
Ovarian Neoplasms
Drug Therapy
docetaxel
Morbidity
Ascites

Keywords

  • HIPEC
  • Ovarian cancer
  • Oxaliplatin
  • Recurrence
  • Secondary cytoreduction

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Fagotti, A., Paris, I., Grimolizzi, F., Fanfani, F., Vizzielli, G., Naldini, A., & Scambia, G. (2009). Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: A pilot study. Gynecologic Oncology, 113(3), 335-340. https://doi.org/10.1016/j.ygyno.2009.03.004

Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients : A pilot study. / Fagotti, A.; Paris, I.; Grimolizzi, F.; Fanfani, F.; Vizzielli, G.; Naldini, A.; Scambia, G.

In: Gynecologic Oncology, Vol. 113, No. 3, 06.2009, p. 335-340.

Research output: Contribution to journalArticle

Fagotti, A, Paris, I, Grimolizzi, F, Fanfani, F, Vizzielli, G, Naldini, A & Scambia, G 2009, 'Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: A pilot study', Gynecologic Oncology, vol. 113, no. 3, pp. 335-340. https://doi.org/10.1016/j.ygyno.2009.03.004
Fagotti, A. ; Paris, I. ; Grimolizzi, F. ; Fanfani, F. ; Vizzielli, G. ; Naldini, A. ; Scambia, G. / Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients : A pilot study. In: Gynecologic Oncology. 2009 ; Vol. 113, No. 3. pp. 335-340.
@article{af5f3a30016542099dd4bd91c878d8f4,
title = "Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: A pilot study",
abstract = "Objectives: To assess feasibility, complications and efficacy of secondary surgical cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in a selected group of platinum-sensitive recurrent ovarian cancer patients. Methods: Recurrent ovarian cancer patients with a platinum-free interval of at least 6 months were prospectively enrolled. After complete CRS they were submitted to intraperitoneal perfusion of oxaplatinum (460 mg/m 2) heated to 41.5 °C for 30 min. Then they received systemic chemotherapy with taxotere 75 mg/m 2 and oxaliplatin 100 mg/m 2 for 6 cycles. Patients were followed up routinely until recurrence or death. Results: Twenty-five recurrent ovarian cancer patients were valuable for the study. The median Platinum Free Interval (PFI) was 25 months (range 7-67). The majority of the patients (76{\%}) had diffuse carcinosis. Nobody had ascites. An optimal residual disease was obtained in all patients. The median duration of CRS + HIPEC was 312 min (range138-619). Median intensive care unit (ICU) stay was 2 days (1-6), median hospital stay was 13 days (7-30). Post-operative major complications were observed in 7 patients (28{\%}). Post-operative mortality was 0{\%}. With a median follow-up time of 18 months (range 3-38), 24 patients (96{\%}) are alive, but seven women (28{\%}) have relapsed. Conclusions: Adequate pre-operative selection can improve feasibility of CRS and HIPEC. Morbidity rate is comparable to aggressive cytoreduction without HIPEC. Although associated with some post-operative morbidity, long-term results are encouraging, waiting for larger series and longer follow-up data.",
keywords = "HIPEC, Ovarian cancer, Oxaliplatin, Recurrence, Secondary cytoreduction",
author = "A. Fagotti and I. Paris and F. Grimolizzi and F. Fanfani and G. Vizzielli and A. Naldini and G. Scambia",
year = "2009",
month = "6",
doi = "10.1016/j.ygyno.2009.03.004",
language = "English",
volume = "113",
pages = "335--340",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients

T2 - A pilot study

AU - Fagotti, A.

AU - Paris, I.

AU - Grimolizzi, F.

AU - Fanfani, F.

AU - Vizzielli, G.

AU - Naldini, A.

AU - Scambia, G.

PY - 2009/6

Y1 - 2009/6

N2 - Objectives: To assess feasibility, complications and efficacy of secondary surgical cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in a selected group of platinum-sensitive recurrent ovarian cancer patients. Methods: Recurrent ovarian cancer patients with a platinum-free interval of at least 6 months were prospectively enrolled. After complete CRS they were submitted to intraperitoneal perfusion of oxaplatinum (460 mg/m 2) heated to 41.5 °C for 30 min. Then they received systemic chemotherapy with taxotere 75 mg/m 2 and oxaliplatin 100 mg/m 2 for 6 cycles. Patients were followed up routinely until recurrence or death. Results: Twenty-five recurrent ovarian cancer patients were valuable for the study. The median Platinum Free Interval (PFI) was 25 months (range 7-67). The majority of the patients (76%) had diffuse carcinosis. Nobody had ascites. An optimal residual disease was obtained in all patients. The median duration of CRS + HIPEC was 312 min (range138-619). Median intensive care unit (ICU) stay was 2 days (1-6), median hospital stay was 13 days (7-30). Post-operative major complications were observed in 7 patients (28%). Post-operative mortality was 0%. With a median follow-up time of 18 months (range 3-38), 24 patients (96%) are alive, but seven women (28%) have relapsed. Conclusions: Adequate pre-operative selection can improve feasibility of CRS and HIPEC. Morbidity rate is comparable to aggressive cytoreduction without HIPEC. Although associated with some post-operative morbidity, long-term results are encouraging, waiting for larger series and longer follow-up data.

AB - Objectives: To assess feasibility, complications and efficacy of secondary surgical cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in a selected group of platinum-sensitive recurrent ovarian cancer patients. Methods: Recurrent ovarian cancer patients with a platinum-free interval of at least 6 months were prospectively enrolled. After complete CRS they were submitted to intraperitoneal perfusion of oxaplatinum (460 mg/m 2) heated to 41.5 °C for 30 min. Then they received systemic chemotherapy with taxotere 75 mg/m 2 and oxaliplatin 100 mg/m 2 for 6 cycles. Patients were followed up routinely until recurrence or death. Results: Twenty-five recurrent ovarian cancer patients were valuable for the study. The median Platinum Free Interval (PFI) was 25 months (range 7-67). The majority of the patients (76%) had diffuse carcinosis. Nobody had ascites. An optimal residual disease was obtained in all patients. The median duration of CRS + HIPEC was 312 min (range138-619). Median intensive care unit (ICU) stay was 2 days (1-6), median hospital stay was 13 days (7-30). Post-operative major complications were observed in 7 patients (28%). Post-operative mortality was 0%. With a median follow-up time of 18 months (range 3-38), 24 patients (96%) are alive, but seven women (28%) have relapsed. Conclusions: Adequate pre-operative selection can improve feasibility of CRS and HIPEC. Morbidity rate is comparable to aggressive cytoreduction without HIPEC. Although associated with some post-operative morbidity, long-term results are encouraging, waiting for larger series and longer follow-up data.

KW - HIPEC

KW - Ovarian cancer

KW - Oxaliplatin

KW - Recurrence

KW - Secondary cytoreduction

UR - http://www.scopus.com/inward/record.url?scp=67349248443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349248443&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2009.03.004

DO - 10.1016/j.ygyno.2009.03.004

M3 - Article

C2 - 19345401

AN - SCOPUS:67349248443

VL - 113

SP - 335

EP - 340

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -